Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v4-FR Version v1-EN
Language French English
Date Updated 2020-05-06 2020-04-20
Drug Identification Number 02286300 02286300
Brand name MITOXANTRONE INJECTION MITOXANTRONE INJECTION
Common or Proper name MitoXANTRONE Injection MitoXANTRONE Injection
Company Name FRESENIUS KABI CANADA LTD FRESENIUS KABI CANADA LTD
Ingredients MITOXANTRONE MITOXANTRONE
Strength(s) 2MG 2MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS INTRAVENOUS INTRAVENOUS
Packaging size 2 mg/mL SD Vial 10 mL 2 mg/mL SD Vial 10 mL
ATC code L01DB L01DB
ATC description CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2020-04-17 2020-04-17
Estimated end date 2020-04-30 2020-04-30
Actual end date 2020-04-30
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments Fresenius Kabi Canada Ltd. is pleased to advise that replenishment inventories of our MitoXANTRONE Injection, 2 mg/mL, SD Vial, 10 mL will be available at all distribution centres today, Thursday, April 30th, 2020 On Backorder
Health Canada comments